Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
44
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

259
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
259
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

131
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
131
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

214
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
214
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

201
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
201
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

648
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
648

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for Next Steps in Our Understanding of Use of Antipsychotics among Older Adults in the PALTC Environments.

Journal of the American Medical Directors Association·2024
Same author

Recommendations for Next Steps in Our Understanding of Use of Antipsychotics Among Older People in the Post-Acute Long-Term Care Environments: Article 3 of 3.

The Senior care pharmacist·2024
Same author

Antipsychotics in Perspective: Past, Present, and Future (Article 2 of 3).

Journal of the American Medical Directors Association·2024
Same author

The AMDA Pain CPG: A Different Kind of Trustworthy Clinical Guideline.

Journal of the American Medical Directors Association·2021
Same author

DEA enforcement in long-term care: is a collaborative correction feasible?

Journal of the American Medical Directors Association·2011
Same author

"Pay for performance": can it help improve long-term care?

Journal of the American Medical Directors Association·2006
Same journal

Can Technology Simplify Aging Care-or Just Shift the Complexity?

The Senior care pharmacist·2026
Same journal

Transitioning Medication-Related Home Visits to a Cognitively Accessible Digital Intervention in Home Care: A Practice Innovation Pilot.

The Senior care pharmacist·2026
Same journal

Perception of Technology to Support Medication Management Among Community-dwelling African American Older Adults.

The Senior care pharmacist·2026
Same journal

ASCP Policy Review Committee.

The Senior care pharmacist·2026
Same journal

Initial Evaluation of L-mMRC Severity Tool in Staging COPD in the Skilled Nursing Setting.

The Senior care pharmacist·2026
Same journal

Dispense This: How AI Is Reshaping Pharmacy's Clinical Services.

The Senior care pharmacist·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.5K

Antipsychotics: Past, Present, and Future (Part 2): Article 2 of 3.

Steven Levenson1

  • 1Post-Acute Long-term Care physician and medical director.

The Senior Care Pharmacist
|January 24, 2024
PubMed
Summary
This summary is machine-generated.

Reducing antipsychotic use in nursing facilities remains challenging despite decades of effort. Past improvement initiatives have yielded fragmented results, highlighting the need for better strategies in psychotropic medication management.

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K

Related Experiment Videos

Last Updated: Jul 5, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.5K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.1K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K

Area of Science:

  • Geriatric Medicine
  • Psychopharmacology
  • Healthcare Policy

Background:

  • The use of antipsychotics in nursing facilities is complex, reflecting broader healthcare system issues.
  • Decades of efforts to reduce unwarranted antipsychotic use have shown limited success, with psychotropic medications still widely prescribed.
  • Current understanding of behavior, person-centered care, and medication use in these settings is incomplete.

Purpose of the Study:

  • To analyze the diverse perspectives and key players involved in past efforts to manage antipsychotic use in nursing facilities.
  • To evaluate the outcomes of these initiatives and identify lessons learned.
  • To lay the groundwork for future recommendations for improving medication management in long-term care.

Main Methods:

  • Review of historical efforts to influence medication use, particularly antipsychotics, in nursing facilities.
  • Analysis of fragmented and often ineffectual improvement initiatives.
  • Examination of the results of interventions targeting psychotropic medication use.

Main Results:

  • Past improvement efforts have been described as fragmented, ineffectual, and politically challenging.
  • Despite significant reductions in indiscriminate antipsychotic use, psychotropics remain prevalent in nursing facilities.
  • The overall improvement in managing residents with dementia and other behavioral issues is unclear.

Conclusions:

  • The history of antipsychotic use in nursing facilities reveals persistent challenges in medication management.
  • Past interventions have not fully resolved the issue of inappropriate psychotropic prescribing.
  • Further research and refined strategies are needed to achieve lasting improvements in person-centered care and medication practices.